← Back to Screener
China SXT Pharmaceuticals, Inc. Class A Ordinary Shares (SXTC)
Price$1.93
Favorite Metrics
Price vs S&P 500 (26W)-103.19%
Price vs S&P 500 (4W)4.24%
Market Capitalization$1.78M
All Metrics
Book Value / Share (Quarterly)$26.14
P/TBV (Annual)2.23x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-12.51%
Cash Flow / Share (Quarterly)$-3.54
Price vs S&P 500 (YTD)-101.87%
Gross Margin (TTM)21.74%
Net Profit Margin (TTM)-576.72%
EPS (TTM)$-161.76
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$-161.76
Revenue Growth (5Y)-19.53%
EPS (Annual)$-348.12
ROI (Annual)-20.33%
Gross Margin (Annual)21.11%
Net Profit Margin (5Y Avg)-185.95%
Cash / Share (Quarterly)$27.35
Revenue Growth QoQ (YoY)-24.46%
ROA (Last FY)-15.25%
Revenue Growth TTM (YoY)-15.42%
EBITD / Share (TTM)$-21.09
ROE (5Y Avg)-27.24%
Operating Margin (TTM)-544.94%
Cash Flow / Share (Annual)$-25.57
P/B Ratio0.09x
P/B Ratio (Quarterly)9.00x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)-11.92x
Net Interest Coverage (TTM)-4.10x
ROA (TTM)-36.94%
EV / EBITDA (TTM)-2.89x
EPS Incl Extra (Annual)$-348.12
Current Ratio (Annual)3.54x
Quick Ratio (Quarterly)4.06x
3-Month Avg Trading Volume0.22M
52-Week Price Return-99.50%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$26.13
P/S Ratio (Annual)1.02x
Asset Turnover (Annual)0.08x
52-Week High$1046.98
Operating Margin (5Y Avg)-162.96%
EPS Excl Extra (Annual)$-348.12
CapEx CAGR (5Y)-65.44%
Tangible BV CAGR (5Y)10.53%
26-Week Price Return-99.21%
Quick Ratio (Annual)3.35x
13-Week Price Return-91.29%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)4.37x
Enterprise Value$-18.331
Revenue / Share Growth (5Y)-18.68%
Asset Turnover (TTM)0.06x
Book Value / Share Growth (5Y)-18.58%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.69x
Pretax Margin (Annual)-189.77%
Cash / Share (Annual)$197.16
3-Month Return Std Dev202.10%
Gross Margin (5Y Avg)35.83%
Net Income / Employee (TTM)$-0
ROE (Last FY)-21.40%
Net Interest Coverage (Annual)-16.84x
EPS Basic Excl Extra (Annual)$-348.12
P/FCF (TTM)4.24x
Receivables Turnover (TTM)1.51x
Total Debt / Equity (Quarterly)0.05x
EPS Incl Extra (TTM)$-161.76
Receivables Turnover (Annual)2.07x
ROI (TTM)-47.26%
P/S Ratio (TTM)1.16x
Pretax Margin (5Y Avg)-184.21%
Revenue / Share (Annual)$183.45
Tangible BV / Share (Annual)$168.06
Price vs S&P 500 (52W)-129.33%
Year-to-Date Return-99.22%
5-Day Price Return-10.14%
EPS Normalized (Annual)$-348.12
ROA (5Y Avg)-14.76%
Net Profit Margin (Annual)-189.77%
Month-to-Date Return10.71%
Cash Flow / Share (TTM)$-21.29
EBITD / Share (Annual)$-271.90
Operating Margin (Annual)-153.97%
LT Debt / Equity (Annual)0.01x
ROI (5Y Avg)-24.05%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-161.76
P/TBV (Quarterly)9.01x
P/B Ratio (Annual)2.22x
Inventory Turnover (TTM)1.49x
Pretax Margin (TTM)-576.72%
Book Value / Share (Annual)$168.19
Price vs S&P 500 (13W)-91.98%
Beta1.81x
P/FCF (Annual)8.49x
Revenue / Share (TTM)$1.99
ROE (TTM)-49.73%
52-Week Low$1.25
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SXTCChina SXT Pharmaceuticals, Inc. Class A Ordinary Shares | 1.16x | -15.42% | 21.74% | — | $1.93 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
China SXT Pharmaceuticals manufactures and markets Traditional Chinese Medicine Pieces (TCMP), specializing in pre-processed, ready-to-use formulations that eliminate decoction. All revenue is generated from the People's Republic of China.